Clinically, DR is an inner retina pathology that begins with the nonproliferative form characterized by alterations in blood flow, death of retinal pericytes, and basement membrane thickening.
3,4 Subsequently, the disease progresses to nonperfusion, microaneurysms, vascular loops, and hemorrhages evident on ophthalmic examination.
5 Ultimately, DR evolves to a proliferative stage, typified by neovascularization, neurodegeneration, and retinal detachment, which cause irreversible vision loss.
6 The cellular mechanisms underlying microvascular complications involve neurovascular cross talk, which is currently under intense scrutiny.
7 There is accumulating evidence that the outer retina, although asymptomatic itself, contributes to these microvascular changes.
8,9 Photoreceptor inner segments, in view of their extremely high metabolic activity,
10 their constitutive production of high amounts of reactive oxygen species (ROS),
11 and their high capacity for mitochondrial oxidative phosphorylation,
12 are attracting increasing attention in the pathophysiology of DR.
13A major hurdle in identifying early pathologic events in DR has been the prevalence of animal models with early onset of diabetes.
13–15 In this study, we relied on the combined advantages of the laboratory rodent
Arvicanthis niloticus: (1) it is a well-established model of T2D
16–18 and of associated retinopathy
19; (2) unlike mouse and rat models, retinopathy progresses in a cone-rich retina (30%–35%, as opposed to 1%–2% in mouse and rat),
20,21 therefore more closely approximating the human macula (cone-dominated area); and (3) unlike mice and rats, Nile rats are diurnal, as humans are.
22 The latter advantage is particularly pertinent in the context that development of T2D has been associated with circadian rhythm disruption via the dysregulation of clock genes.
23